| 23/06 | INSIDER SELL : Allogene Therapeutics |  |
| 17/06 | ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi.. | |
| 13/06 | TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal.. | |
| 08/06 | Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma | |
| 08/06 | Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy.. | |
| 08/06 | Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy .. | |
| 08/06 | Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy .. | |
| 08/06 | Allogene Therapeutics, Inc. Announces the FDA Granted Regenerative Medicine Advanced Th.. | |
| 08/06 | Allogene Therapeutics Gets RMAT Designation for ALLO-501A Lymphoma Treatment | |
| 27/05 | ALLOGENE THERAPEUTICS : ALLO May 2022 Corporate Presentation | |
| 19/05 | Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp.. | |
| 19/05 | Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp.. | |
| 10/05 | TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe.. | |
| 10/05 | Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines.. | |
| 09/05 | Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc.. | |
| 04/05 | TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022 | |
| 04/05 | ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. | |
| 04/05 | ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot | |
| 04/05 | ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K) | |
| 04/05 | Allogene Therapeutics Reports First Quarter 2022 Financial Results | |
| 04/05 | Allogene Therapeutics Reports First Quarter 2022 Financial Results | |
| 04/05 | Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March .. | |
| 28/04 | Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb.. | |
| 28/04 | Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer | |
| 28/04 | Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective M.. | |
| 27/04 | Allogene Secures FDA's Orphan Drug Designation for Multiple Myeloma Drug Candidate | |
| 27/04 | Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022 | |
| 27/04 | Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb.. | |
| 27/04 | Allogene Gets FDA Orphan Designation for ALLO-605 in Multiple Myeloma | |
| 25/04 | ALLOGENE THERAPEUTICS : ALLO April 2022 Corporate Presentation | |
| 14/04 | Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Ta.. | |
| 14/04 | Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility .. | |
| 14/04 | Allogene Therapeutics Unveils Cell Forge 1, A Uniquely Designed Manufacturing Facility .. | |
| 13/04 | Allogene Therapeutics Says Preclinical Data Show ALLO-316 Has Potential to Treat Solid .. | |
| 13/04 | Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candi.. | |
| 12/04 | Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences | |
| 24/03 | Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea.. | |
| 23/03 | Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea.. | |
| 10/03 | Allogene Therapeutics Receives FDA Fast-Track Designation for ALLO-316 to Treat Renal C.. | |
| 10/03 | Allogene Gets FDA Fast-Track Designation for ALLO-316 in Renal Cell Carcinoma | |
| 10/03 | Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Can.. | |
| 10/03 | Allogene Therapeutics, Inc. Receives FDA Fast Track Designation for its First Solid Tum.. | |
| 01/03 | Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Re.. | |
| 24/02 | Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P.. | |
| 23/02 | ALLOGENE THERAPEUTICS : ALLO February 2022 Corporate Presentation | |
| 23/02 | TRANSCRIPT : Allogene Therapeutics, Inc., Q4 2021 Earnings Call, Feb 23, 2022 | |
| 23/02 | ALLOGENE THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pr.. | |
| 23/02 | ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. | |
| 23/02 | ALLOGENE THERAPEUTICS : Q4 Earnings Snapshot | |
| 23/02 | Allogene Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 3.. | |
| 23/02 | Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P.. | |
| 23/02 | Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem.. | |
| 16/02 | Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on F.. | |
| 11/02 | Cellectis' Licensed Partner, Allogene Therapeutics Announces Removal of FDA Clinical Ho.. | |
| 08/02 | ALLOGENE THERAPEUTICS : ALLO January 2022 Corporate Presentation | |
| 26/01 | Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere.. | |
| 18/01 | Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H.. | |
| 14/01 | INSIDER BUY : Allogene Therapeutics | |
| 14/01 | INSIDER BUY : Allogene Therapeutics | |
| 12/01 | Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi.. | |
| 11/01 | ALLOGENE THERAPEUTICS : JPM Presentation 2022 | |
| 11/01 | TRANSCRIPT : Allogene Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Confe.. | |
| 11/01 | Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences | |
| 11/01 | Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini.. | |
| 11/01 | Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi.. | |
| 11/01 | Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical .. | |
| 11/01 | US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy | |
| 11/01 | Antion Biosciences SA announced that it expects to receive funding from Allogene Therap.. | |
| 10/01 | TRANSCRIPT : Allogene Therapeutics, Inc. - Special Call | |
| 10/01 | Allogene Therapeutics' T Cell Trials Off FDA Clinical Hold | |
| 10/01 | ALLOGENE : FDA Lifts Clinical Hold Across AlloCAR T Studies | |
| 10/01 | Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T&trade.. | |
| 10/01 | Allogene Therapeutics, Inc. Announces U.S. Food and Drug Administration Removes Clinica.. | |
| 04/01 | Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conf.. | |
| 2021 | ALLOGENE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (fo.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
